| COINOTAG recommends • Exchange signup |
| 💹 Trade with pro tools |
| Fast execution, robust charts, clean risk controls. |
| 👉 Open account → |
| COINOTAG recommends • Exchange signup |
| 🚀 Smooth orders, clear control |
| Advanced order types and market depth in one view. |
| 👉 Create account → |
| COINOTAG recommends • Exchange signup |
| 📈 Clarity in volatile markets |
| Plan entries & exits, manage positions with discipline. |
| 👉 Sign up → |
| COINOTAG recommends • Exchange signup |
| ⚡ Speed, depth, reliability |
| Execute confidently when timing matters. |
| 👉 Open account → |
| COINOTAG recommends • Exchange signup |
| 🧭 A focused workflow for traders |
| Alerts, watchlists, and a repeatable process. |
| 👉 Get started → |
| COINOTAG recommends • Exchange signup |
| ✅ Data‑driven decisions |
| Focus on process—not noise. |
| 👉 Sign up → |
- Pfizer (PFE) stock has seen a recent boost due to better-than-expected first-quarter sales, largely due to a one-time benefit from Covid drug Paxlovid.
- The pharmaceutical company has also been granted new drug approvals by the FDA, including Tivdak for cervical cancer and Beqvez for hemophilia B.
- However, the company’s revenue from Covid products continues to decline, and it has faced setbacks in its attempts to enter the weight-loss drug market.
Pfizer’s stock performance and recent developments in its product portfolio have investors questioning whether it’s a buy or sell. This article provides an in-depth analysis of the company’s financials, recent news, and market position.
Pfizer’s First-Quarter Report: A ‘Massive’ Upside
Analyst David Risinger from Leerink Partners noted a “massive” upside in Pfizer’s first-quarter report. Despite a 33% fall in adjusted earnings, the company exceeded expectations with sales of $14.88 billion, a 20% decrease from the previous year. Notably, sales of Vyndaqel, a treatment for cardiomyopathy, rose by 66% to $1.14 billion, surpassing projections.
Annual Metrics and Future Projections
Pfizer’s sales have significantly dropped since 2022, with a 42% decrease to nearly $58.5 billion last year. However, the company expects an increase in sales for 2024, projecting earnings of $2.15 to $2.35 per share and $58.5 billion to $61.5 billion in sales.
Recent News and Approvals
Recent FDA approvals for Beqvez, a gene therapy for hemophilia B, and promising results for the new drug Adcetris have put Pfizer in the spotlight. Additionally, the company’s RSV vaccine, Abrysvo, has shown “durable” effectiveness over two years, further strengthening its product portfolio.
| COINOTAG recommends • Professional traders group |
| 💎 Join a professional trading community |
| Work with senior traders, research‑backed setups, and risk‑first frameworks. |
| 👉 Join the group → |
| COINOTAG recommends • Professional traders group |
| 📊 Transparent performance, real process |
| Spot strategies with documented months of triple‑digit runs during strong trends; futures plans use defined R:R and sizing. |
| 👉 Get access → |
| COINOTAG recommends • Professional traders group |
| 🧭 Research → Plan → Execute |
| Daily levels, watchlists, and post‑trade reviews to build consistency. |
| 👉 Join now → |
| COINOTAG recommends • Professional traders group |
| 🛡️ Risk comes first |
| Sizing methods, invalidation rules, and R‑multiples baked into every plan. |
| 👉 Start today → |
| COINOTAG recommends • Professional traders group |
| 🧠 Learn the “why” behind each trade |
| Live breakdowns, playbooks, and framework‑first education. |
| 👉 Join the group → |
| COINOTAG recommends • Professional traders group |
| 🚀 Insider • APEX • INNER CIRCLE |
| Choose the depth you need—tools, coaching, and member rooms. |
| 👉 Explore tiers → |
Technical Analysis of PFE Stock
Despite trading far below its 200-day moving average, Pfizer stock topped its 50-day line on May 1 after reporting its first-quarter earnings. However, it’s important to note that the shares are not currently forming a chart pattern for investors to watch.
Is PFE Stock a Buy or a Sell?
Given the current market conditions and Pfizer’s performance, the stock is not a buy right now. Despite recent gains, Pfizer still needs to prove its fundamental and technical merit. The company’s future growth will largely depend on its adult RSV vaccine and the success of its newly acquired Seagen.
| COINOTAG recommends • Exchange signup |
| 📈 Clear interface, precise orders |
| Sharp entries & exits with actionable alerts. |
| 👉 Create free account → |
| COINOTAG recommends • Exchange signup |
| 🧠 Smarter tools. Better decisions. |
| Depth analytics and risk features in one view. |
| 👉 Sign up → |
| COINOTAG recommends • Exchange signup |
| 🎯 Take control of entries & exits |
| Set alerts, define stops, execute consistently. |
| 👉 Open account → |
| COINOTAG recommends • Exchange signup |
| 🛠️ From idea to execution |
| Turn setups into plans with practical order types. |
| 👉 Join now → |
| COINOTAG recommends • Exchange signup |
| 📋 Trade your plan |
| Watchlists and routing that support focus. |
| 👉 Get started → |
| COINOTAG recommends • Exchange signup |
| 📊 Precision without the noise |
| Data‑first workflows for active traders. |
| 👉 Sign up → |
Conclusion
While Pfizer’s recent performance and new product approvals have boosted its stock, the company faces challenges in maintaining this momentum. Investors should keep a close eye on Pfizer’s upcoming developments and market performance to make informed decisions.
| COINOTAG recommends • Members‑only research |
| 📌 Curated setups, clearly explained |
| Entry, invalidation, targets, and R:R defined before execution. |
| 👉 Get access → |
| COINOTAG recommends • Members‑only research |
| 🧠 Data‑led decision making |
| Technical + flow + context synthesized into actionable plans. |
| 👉 Join now → |
| COINOTAG recommends • Members‑only research |
| 🧱 Consistency over hype |
| Repeatable rules, realistic expectations, and a calmer mindset. |
| 👉 Get access → |
| COINOTAG recommends • Members‑only research |
| 🕒 Patience is an edge |
| Wait for confirmation and manage risk with checklists. |
| 👉 Join now → |
| COINOTAG recommends • Members‑only research |
| 💼 Professional mentorship |
| Guidance from seasoned traders and structured feedback loops. |
| 👉 Get access → |
| COINOTAG recommends • Members‑only research |
| 🧮 Track • Review • Improve |
| Documented PnL tracking and post‑mortems to accelerate learning. |
| 👉 Join now → |